Category Covid-19

PIER MARIA FORNASARI
2021-12-13

FDA issued an EUA for New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in patients with moderate to severely compromised immune systems or a history of severe adverse reactions to a COVID-19 vaccine

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  The product is only authorized

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-13

A new brief of Health System Tracker examines how deaths from COVID-19 rank among other leading causes of death in the U.S. and vaccine saving of 163.000 deaths since June 2021.

This brief examines how deaths from COVID-19 rank among other leading causes of death in the U.S. We find that COVID-19 was the third leading cause of death in November 2021. We also find that in October, COVID-19 was the number 1 cause of death for people age 45-54 and in the top 7 leading

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-10

Israel study shows that booster receivers at least 5 months after a second dose of BNT162b2 had 90% lower mortality due to Covid-19.

Booster doses of Pfizer’s coronavirus vaccine set recipients up to effectively withstand the ravages of both the Delta and Omicron variants, a group of new studies suggest. Boosted folks are 90% less likely to die from a Delta infection than people relying solely on the initial two-dose vaccination, Israeli data show. That protection will be critically important

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-10

3 Teens with COVID-19 Developed Sudden Severe Psychiatric Symptoms. Why?

UCSF-Led Study Shows Unruly Immune System May Trigger ‘Turncoat’ Antibodies Suicidal thoughts, “paranoia-like fears,” delusions and “foggy brain” have been identified in three adolescents who had mild or asymptomatic COVID-19. Now, a new study into their immune responses identifies a potential mechanism by which these symptoms emerged. The study, led by researchers at the UCSF Weill

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-05

Early Features on South Africa Tshwane District Omicron Variant Patient Profile: absence of any significant increase in in-hospitals deaths in relation to the dramatic rise in the case rate.

There has been a significant rise in new SARS-CoV-2 infections in the Gauteng Province in the last four weeks which has been attributed to the new Omicron variant announced on 24 November 2021. The first cases of Omicron were detected in the Tshwane District and coincided with the sharp rise in new infections, heralding the

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-05

The first six months of COVID-19 vaccination campaign in Italy averted 29350 deaths and 4256332 new infections: results published in a paper of Greenwich, Boston and Indiana Universities

In a paper published in MedRxiv are analyzed the effectiveness of the first six months of vaccination campaign against SARS-CoV-2 in Italy by using a computational epidemic model which takes into account demographic, mobility, vaccines, as well as estimates of the introduction and spreading of the more transmissible Alpha variant. Are considered six sub-national regions

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-05

Researchers reveal possible role for anti-idiotype antibodies in long-term effects of COVID-19 and some vaccines complications

With around 256 million cases and more than 5 million deaths worldwide, the COVID-19 pandemic has challenged scientists and those in the medical field. Researchers are working to find effective vaccines and therapies, as well as understand the long-term effects of the infection. While the vaccines have been critical in pandemic control, researchers are still

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2021-12-05

High-titre convalescent plasma therapy not effective against severe COVID-19 pneumonia: results of Italian TSUNAMI randomized clinical trial

1. Amongst patients with severe COVID-19 pneumonia, there was no difference in 30-day all-cause mortality, ventilation or cure in patients receiving convalescent plasma (CP) plus standard therapy versus standard therapy alone. 2. CP treatment was associated with more adverse events, including 5 instances of respiratory failure requiring treatment interruption. Patients who have recovered from SARS-CoV-2

Read More

No Comments InCovid-19